Project Grant R01EY037747
- The National Eye Institute awarded the Regents of the University of Michigan $342,349 on August 1, 2026, under the Vision Research program (CFDA 93.867) to investigate the computational and neural mechanisms of visuocognitive adaptation. The research examines how the brain adaptively modulates visual and cognitive processes in response to environmental changes, fatigue, injury, and disease. The project tests whether error-based adaptation in spatial working memory and eye movements shares...
- The National Eye Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $624,743 to the Regents of the University of California, doing business as University of California, Berkeley, on May 1, 2026, under the Vision Research program (CFDA 93.867). The award funds research into the function and regulation of constitutive prostaglandin D2 and DP receptor signaling in retinal health and neurodegeneration. The research investigates the physiological and...
- The National Eye Institute awarded the University of Pennsylvania $674,423 on September 1, 2026, under the Vision Research program (CFDA 93.867) to investigate the role of retinal microsomal triglyceride transfer protein (MTP) in vision and lipid homeostasis. The research examines how MTP regulates the assembly and secretion of apoprotein B-containing lipoproteins in the retinal pigment epithelium (RPE), which transport lipids and prevent pathologic lipid accumulation linked to retinal...
- The National Eye Institute, part of the Department of Health and Human Services, awarded $458,288 to the University of Washington on May 1, 2026, under the Vision Research program (CFDA 93.867, Assistance Listing designation Project Grant). The award funds research into stimulation of regeneration in the human retina. The investigator team will test whether expressing the proneural regulatory gene ASCL1 in Müller glia can induce regeneration of retinal neurons in human tissue and adult non-human...
- The National Eye Institute awarded The University of Chicago $582,115 on September 1, 2026, under the Vision Research program (CFDA 93.867) to investigate the role of lens connexins, cellular stress, and ionic imbalance in cataract formation. The research will define pathogenic mechanisms linking disruption of lens ionic homeostasis and formation of calcium-containing deposits to cataract development. The project utilizes human lens material, mutant mouse models, and in vitro systems to...
- The National Eye Institute awarded The Research Foundation For The State University Of New York $248,737 on June 1, 2026, under the Vision Research program (CFDA 93.867) to support research on the role of mitochondrial and autophagy dysfunction in regulating inflammatory processes during age-related macular degeneration pathogenesis. The award funds investigation into the deregulation of autophagy and heightened inflammation implicated in dry AMD, the leading cause of blindness in the elderly...
- The National Eye Institute awarded the University of Rochester a $2,215,463 cooperative agreement on March 17, 2026, under the Vision Research program (CFDA 93.867) to develop small molecule PROTAC compounds targeting secretory phospholipase A2-IIA (SPLA2-IIA) for treatment of age-related macular degeneration and related macular dystrophies. The award funds development of proteolysis-targeting chimera compounds designed to induce degradation of SPLA2-IIA, a pro-inflammatory enzyme identified...
- The National Eye Institute awarded The University of Iowa $440,263 on May 1, 2026, under the Vision Research program (CFDA 93.867) to investigate osmotic regulation in cone dystrophy with supernormal rod response (CDSRR), a rare inherited retinal disease causing progressive vision loss beginning in early childhood. The project uses state-of-the-art imaging biomarkers and transcriptomics to evaluate osmotic regulation in mouse models of CDSRR, a disease caused by mutations in the KV2.1/KV8.2...
- The National Eye Institute awarded Baylor College of Medicine $1.6 million on September 30, 2025, under the Vision Research program (CFDA 93.867) to conduct basic research on Hippo and Wnt pathway regulation of mammalian Müller glial cell reprogramming and proliferation as a strategy for retinal regeneration in glaucoma, macular degeneration, diabetic retinopathy, and traumatic retinal injury. The research employs genetic loss- and gain-of-function experiments, fate mapping, and single-cell...
- The National Eye Institute awarded The Schepens Eye Research Institute $858,394 on August 1, 2026, under the Vision Research program (CFDA 93.867) to develop multimodal foundation models for eye disease screening and prognosis. The research develops a vision-language foundation model trained on pairs of retinal images and clinical notes to enable downstream supervised models for detection and progression prediction of age-related macular degeneration, diabetic retinopathy, and glaucoma. The...
The National Eye Institute awarded the Regents of the University of Michigan $519,644 on August 1, 2026, under the Vision Research program (CFDA 93.867) to investigate the metabolic and molecular mechanisms by which glutamine promotes photoreceptor health and survival. The research addresses photoreceptor death as a cause of vision loss in retinal diseases. The recipient's work defines the downstream metabolic and molecular pathways by which glutamine catabolism impacts rod photoreceptor health, building on preliminary findings that rod photoreceptors are highly dependent on glutamine catabolism to maintain biomass and survival. The investigation tests the hypothesis that glutaminase-driven glutamine catabolism in rod photoreceptors supports the production of aspartate and asparagine to promote anabolism and prevent activation of pro-apoptotic stress pathways. This research is expected to reveal new therapeutic targets for preventing vision loss and complement an ongoing phase I/II trial investigating gene therapy that stimulates glucose metabolism in photoreceptors to treat retinal disease. Work is performed at the University of Michigan, Ann Arbor, Michigan. The period of performance runs through April 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $519.6k | 8/3/26 |